
Why Your Appointment May Take Longer Than Anticipated
We often have patients and family members ask why they have to wait or why their appointment is taking so long, especially if they see other patients called back before them. We
read more
Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting
On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase
read more
Dr. Nikisha Kothari Selected as “One to Watch” in Retina Today
Texas Retina’s Dr. Nikisha Kothari has been selected as a “One to Watch” in the July/August issue of Retina Today. This feature highlights individuals identified as future leaders in the field of
read more
July is UV Safety Month — Debunking Seven Common Myths About Sunglasses
When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July
read more
June is Fireworks Eye Safety Awareness Month
Summer is here, and for many that means outdoor celebrations that include fireworks, especially around the 4th of July. Unfortunately, this also means an increase in eye injuries. Here are a few
read more
New Wichita Falls Office Open House
On June 16, 2025, our Texas Retina Wichita Falls team hosted an open house event to welcome physicians and staff from nearby medical offices to meet Rocío Díaz, MD, and to see
read more
Initial Results of Phase Ib LOTUS Clinical Trial on Potential New Diabetic Macular Edema Treatment Released
On June 9, 2025, Eluminex Biosciences Limited, a clinical-stage protein therapeutics company, announced positive topline safety, tolerability, and pharmacodynamic data from the multicenter LOTUS Part 1 clinical trial of EB-105 in patients
read more
Dr. Abbey Discusses How Vorolanib Could Shift the Treatment Approach for Diabetic Macular Edema in New Retinal Physician Article
Texas Retina’s Ashkan M. Abbey, MD, served as a principal site investigator for the Phase II VERONA clinical trial evaluating the efficacy and safety of the vorolanib intravitreal insert (EYP-1901) in diabetic
read more